WP-1303 Phase 3 combination study
Phase 3
Terminated
- Conditions
- primary open-angle glaucoma, ocular hypertension
- Registration Number
- JPRN-jRCT2080224837
- Lead Sponsor
- Wakamoto pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- terminated
- Sex
- All
- Target Recruitment
- 280
Inclusion Criteria
Patients with POAG or OH.
IOP is less than 35 mmHg for both eyes.
IOP aftre latanoplost treated is greater than or equal to 18mmHg.
Exclusion Criteria
Patients who have visual acuity of less than 0.3.
Presence of active eye disease (eg., uveitis, ocular infection, severe dry eye).
Pregnant women, lactating women or women who desire to be pregnant.
Patients who is judged inappropriate to participate in the study by investigator or sub-investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety<br>efficacy<br>efficacy:intraocular pressure<br>safety:adverse event and adverse drug reaction
- Secondary Outcome Measures
Name Time Method efficacy<br>efficacy:intraocular pressure